# Anthrax-rPA: Safety, Tolerability, Immunogenicity

> **NCT00063843** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 80 (—)

## Conditions studied

- Anthrax

## Interventions

- **BIOLOGICAL:** Recombinant Protective Antigen, Anthrax Vaccine Adsorbed

## Key facts

- **NCT ID:** NCT00063843
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 80 (—)
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063843, "Anthrax-rPA: Safety, Tolerability, Immunogenicity". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00063843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*